patent cliff

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.

Novartis offers better dividend yields and diversification than Merck, with stronger long-term prospects despite both beating the S&P 500.

Bristol Myers Squibb trades at attractive 9.5x forward P/E with 4.2% yield and 17 years of dividend hikes, but faces revenue declines and patent expiration risks.

AbbVie maintains 10+ years of consecutive dividend increases despite Humira patent loss, buoyed by blockbuster drugs Skyrizi and Rinvoq projected to reach $50B by 2030.

Eli Lilly commits $10B to AI drug discovery partnership and sleep disorders acquisition, diversifying beyond its GLP-1 franchise.

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.

Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

Healthcare sector faces pullback amid Middle East tensions, but dividend-paying stocks and funds offer yields of 6-14.1% with varying risk profiles.

Catalyst Pharmaceuticals trades at 20-33% discount to peers with 7.5% FCF yield; 2026 Hetero litigation is binary catalyst determining if shares reach $28-32 or collapse to $16-20.

BMY and MDT offer attractive dividend yields and growth potential, with BMY at 4% yield and MDT boasting 48 years of consecutive increases.

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.

Novartis maintains growth despite patent challenges, backed by a strong product portfolio of 15 billion-dollar brands and nearly 30 years of consecutive dividend increases.

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.